Atreca Announces Pricing of Initial Public Offering
June 19 2019 - 9:40PM
Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing
its differentiated platform to discover and develop novel
antibody-based immunotherapeutics to treat a range of solid tumor
types, today announced the pricing of its initial public offering
of 7,350,000 shares of common stock at a price to the public of
$17.00 per share.
In addition, Atreca has granted the underwriters a
30-day option to purchase up to 1,102,500 additional shares of
common stock at the initial public offering price, less
underwriting discounts and commissions. The shares are expected to
begin trading on The Nasdaq Global Select Market under the symbol
“BCEL” on June 20, 2019, and the offering is expected to close on
June 24, 2019, subject to customary closing conditions. Atreca
estimates net proceeds from the offering will be approximately
$113.8 million (assuming no exercise of the underwriters’ option to
purchase additional shares of common stock), after deducting the
underwriting discounts and commissions and estimated offering
expenses payable by Atreca.
Cowen, Evercore ISI, and Stifel are acting as joint book-running
managers for the offering. Canaccord Genuity is acting as a lead
manager for the offering. Arcadia Securities is acting as
co-manager for the offering.
The offering is being made only by means of a prospectus. Copies
of the final prospectus, when available, may be obtained from:
Cowen and Company, LLC, c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, by telephone at (631) 274-2806, or by email at
PostSaleManualRequests@broadridge.com; Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor,
New York, New York 10055, by email at ecm.prospectus@evercore.com,
or by telephone at (888) 474-0200; or Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, California 94104, or by telephone at
415-364-2720 or by email at syndprospectus@stifel.com.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Atreca
Atreca is a biopharmaceutical company utilizing its
differentiated platform to discover and develop novel
antibody-based immunotherapeutics to treat a range of solid tumor
types. While more traditional oncology drug discovery approaches
attempt to generate antibodies against known targets, Atreca’s
approach relies on the human immune system to direct it to unique
antibody-target pairs from patients experiencing a clinically
meaningful, active immune response against their tumors. These
unique antibody-target pairs represent a potentially novel and
previously unexplored landscape of immuno-oncology targets.
Atreca Media Contacts: Nancie
Steinberg212-213-0006, ext.
318nsteinberg@burnsmc.com
Robert Flamm212-213-0006, ext. 364rflamm@burnsmc.com
Investor RelationsHerb
Cross650-453-5217ir@atreca.com
Alex Gray212-213-0006, ext. 355agray@burnsmc.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024